STOCKHOLM – Elekta AB (EKTA-B.ST) announces that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective today, November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.
","regulatory":true},{"id":2772,"name":"Elekta’s Nomination Committee for the Annual General Meeting 2025","url":"https://ir.elekta.com/investors/press-releases/2024/elektas-nomination-committee-for-the-annual-general-meeting-2025/","date":"2024-10-31T06:30:00.000Z","intro":"STOCKHOLM, Sweden – In accordance with the resolution passed by Elekta’s (EKTA-B.ST) Annual General Meeting on September 5, 2024, the Chairman of the Board has convened the Nomination Committee for the Annual General Meeting 2025 by contacting the company’s largest shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the Annual General Meeting 2024.
","regulatory":false},{"id":2770,"name":"First major advance in radiation treatment for high-grade gliomas in more than 25 years presented at ASTRO 2024","url":"https://ir.elekta.com/investors/press-releases/2024/first-major-advance-in-radiation-treatment-for-high-grade-gliomas-in-more-than-25-years-presented-at-astro-2024/","date":"2024-10-01T11:30:00.000Z","intro":"The UNITED trial demonstrates that radiation exposure to healthy brain can be minimized without compromising control for this aggressive type of brain tumor
","regulatory":false},{"id":2769,"name":"Elekta issues a SEK 1.5 billion bond and signs a revolving credit facility of SEK 1 billion","url":"https://ir.elekta.com/investors/press-releases/2024/elekta-issues-a-sek-1-5-billion-bond-and-signs-a-revolving-credit-facility-of-sek-1-billion/","date":"2024-10-01T05:30:00.000Z","intro":"STOCKHOLM – Elekta (EKTA-B.ST) announced today that it has issued a SEK 1.5 billion bond under its existing Medium Term Note Program with a total limit of SEK 5 billion. The bond is divided into three tranches with floating rates:
","regulatory":false},{"id":2766,"name":"Elekta Evo submitted to U.S. FDA for premarket approval – to be featured at ASTRO","url":"https://ir.elekta.com/investors/press-releases/2024/elekta-evo-submitted-to-u-s-fda-for-premarket-approval-to-be-featured-at-astro/","date":"2024-09-24T05:30:00.000Z","intro":"STOCKHOLM – Elekta (EKTA-B.ST) announced today that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo* has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) – this, less than a week after Evo received CE mark for sales and marketing in the European Union.
","regulatory":false}]